NCT05189067 2022-01-12Efficacy and Safety of Adjuvant Docetaxel and Trastuzumab in Stage I HER2-positive Breast CancerSecond Affiliated Hospital, School of Medicine, Zhejiang UniversityPhase 2/3 Unknown190 enrolled